Page 52 - Aet News Today

At RSNA 2023, AI startup Hoppr announced that it teamed up with AWS to launch a new foundation model. The product, named Grace, is a B2B model designed to help application developers build better AI solutions for the medical imaging field — and to build them more quickly.

I work as a cardiologist for a multi-specialty group that sees patients both in capitated payer and fee-for-service environments. This diverse practice gives me the experience to know where insurance providers will find value or what they will likely pay for. As these protocols become more scientifically validated, AI is going to help the entire healthcare system to identify at-risk patients quickly and accurately.

There needs to be better communication, a focus on clinically appropriate care and more empathy when it comes to treating the mental health of the incarcerated population, executives said during a recent panel discussion.

While current government and commercial efforts to negotiate competitive drug prices are important, this focus represents a minor—and misplaced—implementation of medication management. It’s time that policymakers, insurers and healthcare providers make pharmacogenomic testing a fundamental standard of care delivery.

Sunnyside, which offers an app to help consumers moderate their drinking, has raised $11.5 million in Series A funding. The round was led by Motley Fool Ventures and will be partially used for product development.

With proposed requirements ranging from accessible self-service kiosks to accessible medical equipment, the impact of this new rule will be wide-ranging with financial, operational, and practical consequences.

Proposals targeting misaligned financial incentives, price transparency, and pharmacy access are important and necessary reforms. But the consequences of failing to address pharmacy benefit managers’ use of market power to block competition and extract monopoly profits from payers and consumers will not be limited to drug costs – it will change all of healthcare for generations.

BeiGene is expanding its cancer drug pipeline, landing global rights to an Ensem Therapeutics cancer drug candidate ready to enter the clinic. The drug targets CDK2, an enzyme whose excessive activity is associated with cancer progression.

Eating disorders don't discriminate. Equip, a virtual company that provides eating disorder support, is trying to reach different populations by having a diverse care team and working with advisors from different backgrounds, said Kristina Saffran, CEO and co-founder of the company.

The DEA proposed a rule back in March that would roll back some of the Covid-19 flexibilities for the virtual prescribing of controlled substances, but has since extended the flexibilities. Stephanie Strong, founder and CEO of Boulder Care, feels confident that the DEA will continue to be open to the prescribing of these medications via telemedicine.